Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics | Zendy

Volker Wacheck | Zendy; Michael Lahn | Zendy; Gemma L. Dickinson | Zendy; Wolfgang Füreder | Zendy; Renata A. Meyer | Zendy; Susanne Herndlhofer | Zendy; Thorsten Füreder | Zendy; Georg Dorfner | Zendy; Sada Pillay | Zendy; Valérie André | Zendy; Timothy P Burkholder | Zendy; Jacqueline K. Akunda | Zendy; Leann Flye-Blakemore | Zendy; Dirk Van Bockstaele | Zendy; Richard F. Schlenk | Zendy; Wolfgang R. Sperr | Zendy; Peter Valent | Zendy

Open Access

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics

Author(s) -

Volker Wacheck,

Michael Lahn,

Gemma L. Dickinson,

Wolfgang Füreder,

Renata A. Meyer,

Susanne Herndlhofer,

Thorsten Füreder,

Georg Dorfner,

Sada Pillay,

Valérie André,

Timothy P Burkholder,

Jacqueline K. Akunda,

Leann Flye-Blakemore,

Dirk Van Bockstaele,

Richard F. Schlenk,

Wolfgang R. Sperr,

Peter Valent

Publication year - 2011

Publication title -

cancer management and research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.024

H-Index - 40

ISSN - 1179-1322

DOI - 10.2147/cmr.s19341

Subject(s) - pharmacokinetics , pharmacodynamics , myeloid leukemia , medicine , pharmacology , leukemia , oncology

Acute myeloid leukemia (AML) is a life-threatening malignancy with limited treatment options in chemotherapy-refractory patients. A first-in-human dose study was designed to investigate a safe and biologically effective dose range for LY2457546, a novel multikinase inhibitor, in patients with relapsed AML.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research